Brad Gouker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Brad Gouker has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Amy James
Animal research Technical Support, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
15 shared publications - Baktiar O. Karim
Frederick National Laboratory for Cancer Research
15 shared publications - Carleen Klumpp-Thomas
National Center for Advancing Translational Sciences
15 shared publications - Catherine Wells
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
15 shared publications - Christine M. Heske
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
15 shared publications - Christopher J. Ricketts
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
15 shared publications
Latest Publications
- Open Access
Metabolic maintenance of breast cancer cells and metastases through E-cadherin/YAP–dependent pyruvate carboxylase expression
Epithelial-mesenchymal transition (EMT) and glycolytic metabolism are well-characterized drivers of cancer progression and metastasis. However, most primary breast tumors and metastases express E-cadherin and the epithelial phenotype is associated with mitochondrial oxidative metabolism, yet the causality and relevance of these relationships and their underlying mechanisms remain poorly understood. Using a 3D culture model with mechano-stimulation, we found that E-cadherin promotes mitochondrial oxidative phosphorylation (OXPHOS) while reducing oxidative stress. Through pharmacological and genetic manipulations of inflammatory breast cancer (IBC) and/or triple negative breast cancer (TNBC) cell lines, we identified pyruvate carboxylase (PC) as an E-cadherin effector. Critically, restoring PC in E-cadherin-silenced cells rescued mitochondrial oxygen consumption and protection from oxidative stress. Co-expression of E-cadherin and PC was confirmed in breast cancer tissues and experimental lung metastases. Mechanistically, E-cadherin induced PC expression and OXPHOS via AKT-mediated activation of YAP/ /TEAD transcription factors, which are better known as supporting EMT. Clinically relevant AKT and TEAD inhibitors reduced both PC expression and oxidative respiration. Importantly, PC inhibition as monotherapy attenuated established experimental lung metastases and primary tumor burden in mice. Taken together, these findings reveal that E-cadherin-mediated cell-cell adhesions directly support mitochondrial metabolism through AKT–YAP/TEAD–PC signaling, identifying a therapeutic vulnerability in metastatic epithelial TNBC.
Open AccessMetabolic maintenance of breast cancer cells and metastases through E-cadherin/YAP–dependent pyruvate carboxylase expression
Epithelial-mesenchymal transition (EMT) and glycolytic metabolism are well-characterized drivers of cancer progression and metastasis. However, most primary breast tumors and metastases express E-cadherin and the epithelial phenotype is associated with mitochondrial oxidative metabolism, yet the causality and relevance of these relationships and their underlying mechanisms remain poorly understood. Using a 3D culture model with mechano-stimulation, we found that E-cadherin promotes mitochondrial oxidative phosphorylation (OXPHOS) while reducing oxidative stress. Through pharmacological and genetic manipulations of inflammatory breast cancer (IBC) and/or triple negative breast cancer (TNBC) cell lines, we identified pyruvate carboxylase (PC) as an E-cadherin effector. Critically, restoring PC in E-cadherin-silenced cells rescued mitochondrial oxygen consumption and protection from oxidative stress. Co-expression of E-cadherin and PC was confirmed in breast cancer tissues and experimental lung metastases. Mechanistically, E-cadherin induced PC expression and OXPHOS via AKT-mediated activation of YAP/ /TEAD transcription factors, which are better known as supporting EMT. Clinically relevant AKT and TEAD inhibitors reduced both PC expression and oxidative respiration. Importantly, PC inhibition as monotherapy attenuated established experimental lung metastases and primary tumor burden in mice. Taken together, these findings reveal that E-cadherin-mediated cell-cell adhesions directly support mitochondrial metabolism through AKT–YAP/TEAD–PC signaling, identifying a therapeutic vulnerability in metastatic epithelial TNBC.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Structural figures of NAMPT inhibitors.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Structural figures of NAMPT inhibitors.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Time course study design for imaging and OT-82 treatment for hyperpolarized pyruvate 13C-MRSI. Post treatment MRSI was performed 5 hours post OT-82 dose #2.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Time course study design for imaging and OT-82 treatment for hyperpolarized pyruvate 13C-MRSI. Post treatment MRSI was performed 5 hours post OT-82 dose #2.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Cell proliferation rates of HLRCC cell lines treated with low and high concentrations of NAMPT inhibitors. A) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK262 after 96 hours. B) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK268 after 96 hours. C) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK365 after 96 hours.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Cell proliferation rates of HLRCC cell lines treated with low and high concentrations of NAMPT inhibitors. A) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK262 after 96 hours. B) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK268 after 96 hours. C) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK365 after 96 hours.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
HLRCC spheroid characterization and OT-82 effect on 3D culture. A) UOK262 and (B) UOK365 spheroids plated at different cell densities (8000, 4000, and 2000 cells/well in triplicate) after 24h, showing different degrees of cell aggregation. Cell viability of UOK262 (C) and UOK365 (D) spheroids treated with GNE-618 (1 nM-500 nM) or OT-82 (0.2 nM-100 nM) assessed with Cell-Titer Glo 3D assay decreases in a dose dependent manner.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
HLRCC spheroid characterization and OT-82 effect on 3D culture. A) UOK262 and (B) UOK365 spheroids plated at different cell densities (8000, 4000, and 2000 cells/well in triplicate) after 24h, showing different degrees of cell aggregation. Cell viability of UOK262 (C) and UOK365 (D) spheroids treated with GNE-618 (1 nM-500 nM) or OT-82 (0.2 nM-100 nM) assessed with Cell-Titer Glo 3D assay decreases in a dose dependent manner.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
NAD+ and NADH analysis of UOK365 cells. Analysis of the relative levels of NAD+ and NADH and their ratio after 24 hour treatment of the UOK365 cell line model with a range of concentrations (0.5-100 nM) of either GNE-618 (A-B) or OT-82 (C-D). All levels were compared to cells treated with the amount of DMSO present in the highest concentration of the utilized drugs.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
NAD+ and NADH analysis of UOK365 cells. Analysis of the relative levels of NAD+ and NADH and their ratio after 24 hour treatment of the UOK365 cell line model with a range of concentrations (0.5-100 nM) of either GNE-618 (A-B) or OT-82 (C-D). All levels were compared to cells treated with the amount of DMSO present in the highest concentration of the utilized drugs.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
In vitro analysis of NAMPT inhibition on glycolysis in FH-deficient tumor cells. (A) Effects of the NAMPT inhibitor OT-82 (100 nM) on the extracellular acidification rate (ECAR) in the UOK262 and UOK365 HLRCC cell lines and the RPTEC normal cell line. (B) Representation of the different effects of OT-82 versus DMSO at time point 5 (designated by a star) after the injection of glucose in UOK262, UOK365, and RPTEC. 2-DG, 2-deoxyglucose.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
In vitro analysis of NAMPT inhibition on glycolysis in FH-deficient tumor cells. (A) Effects of the NAMPT inhibitor OT-82 (100 nM) on the extracellular acidification rate (ECAR) in the UOK262 and UOK365 HLRCC cell lines and the RPTEC normal cell line. (B) Representation of the different effects of OT-82 versus DMSO at time point 5 (designated by a star) after the injection of glucose in UOK262, UOK365, and RPTEC. 2-DG, 2-deoxyglucose.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Validation of MIPE hits in 96-well cytotoxicity screens and comparison of NAMPT inhibitor efficacy across a panel of HLRCC cell lines.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Validation of MIPE hits in 96-well cytotoxicity screens and comparison of NAMPT inhibitor efficacy across a panel of HLRCC cell lines.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
In vivo effects of NAMPT inhibitors in HLRCC xenograft models. Mean body weights are constant throughout the drug study for animals harboring UOK262 xenografts (A) and UOK365 xenografts (B; study shown in Figure 3A-B, n = 10 mice per arm, 95mg/kg OT-82 for 8 week duration). (C-D) H&E stained sections of retinas obtained from NSG mice treated with vehicle or 95mg/kg OT-82 for 5 days. (E-F) Caspase 3 stained sections of retinas obtained from NSG mice treated with vehicle or 95 mg/kg OT-82 for 5 days. Histological sections were evaluated for signs of retinal toxicity by a trained veterinary pathologist. No overt signs of retinal toxicity were observed (n=3 NSG mice).
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
In vivo effects of NAMPT inhibitors in HLRCC xenograft models. Mean body weights are constant throughout the drug study for animals harboring UOK262 xenografts (A) and UOK365 xenografts (B; study shown in Figure 3A-B, n = 10 mice per arm, 95mg/kg OT-82 for 8 week duration). (C-D) H&E stained sections of retinas obtained from NSG mice treated with vehicle or 95mg/kg OT-82 for 5 days. (E-F) Caspase 3 stained sections of retinas obtained from NSG mice treated with vehicle or 95 mg/kg OT-82 for 5 days. Histological sections were evaluated for signs of retinal toxicity by a trained veterinary pathologist. No overt signs of retinal toxicity were observed (n=3 NSG mice).
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Expression levels of NAD+ biosynthetic and salvage pathway genes in HLRCC tumors, normal kidney samples and pan-kidney data from TCGA. (A) Overview of NAD+ biosynthetic and salvage pathways. (B-E) Box plots for selected NAD+ biosynthetic genes derived from RNA-seq analysis of HLRCC tumors and normal kidney specimens. (F) Box plots for selected NAD+ biosynthetic genes derived from RNA-seq TCGA pan-kidney data. NAMPT (nicotinamide phosphoribosyltransferase), NAPRT (nicotinate phosphoribosyltransferase ), QPRT (quinolinate phosphoribosyltransferase), NMNAT (nicotinamide mononucleotide adenylyl transferase), KIRP (kidney renal papillary cancer), CIMP (CpG island methylator phenotype), PRCC T1/T2 (papillary renal cell carcinoma type 1/type 2), ccRCC (clear cell renal cell carcinoma), ChRCC (chromophobe renal cell carcinoma).
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Expression levels of NAD+ biosynthetic and salvage pathway genes in HLRCC tumors, normal kidney samples and pan-kidney data from TCGA. (A) Overview of NAD+ biosynthetic and salvage pathways. (B-E) Box plots for selected NAD+ biosynthetic genes derived from RNA-seq analysis of HLRCC tumors and normal kidney specimens. (F) Box plots for selected NAD+ biosynthetic genes derived from RNA-seq TCGA pan-kidney data. NAMPT (nicotinamide phosphoribosyltransferase), NAPRT (nicotinate phosphoribosyltransferase ), QPRT (quinolinate phosphoribosyltransferase), NMNAT (nicotinamide mononucleotide adenylyl transferase), KIRP (kidney renal papillary cancer), CIMP (CpG island methylator phenotype), PRCC T1/T2 (papillary renal cell carcinoma type 1/type 2), ccRCC (clear cell renal cell carcinoma), ChRCC (chromophobe renal cell carcinoma).